Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTEGRATE: Efficacy, Tolerability and Safety of New or Repurposed Drugs Against Lassa Fever
NCT06212336Phase 3Recruiting
- Sponsor
- Irrua Specialist Teaching Hospital
- Start
- May 2025
- Primary completion
- Jun 2027
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of favipiravir, dexamethasone, ARN-75039 in Lassa fever, sponsored by Irrua Specialist Teaching Hospital. Started May 2025; status: recruiting.
02
Drugs
favipiravirdexamethasoneARN-75039
03
Conditions
Lassa fever
Beyond the preview
Go deeper on NCT06212336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06212336.